NG Bio

Mesenbio is a preclinical biopharmaceutical company based at the University of York, specializing in cell-derived therapies. It has developed a unique technique known as Cell Line Extracellular Vesicle Release (CLEVR), which aims to enhance the treatment pipeline by addressing significant challenges in extracellular vesicle therapy. The company focuses on creating innovative treatments, including a novel therapy for arthritis derived from engineered human stem cells. By unlocking the potential of extracellular vesicles, Mesenbio seeks to transform medical approaches to musculoskeletal diseases, thereby providing more effective therapeutic options.

Bastion Therapeutics is a preclinical biotechnology company developing proprietary platform technology to enhance regulatory T cells (Tregs) for immune system modulation.